Recipharm equips a further three facilities for US serialisation
Recipharm, a leading contract development and manufacturing organisation (CDMO) has equipped three more of its facilities with serialisation capabilities in line with the US regulatory requirements in time for today’s introduction of the Drug Supply Chain Security Act (DSCSA).
The facilities in Brescia, Italy and Karlskoga and Uppsala, Sweden, are the latest of Recipharm’s sites to be equipped to supply serialised products to the US and take the total number of facilities able to offer serialisation capabilities to nine.
Following a EUR 40 million investment into its company-wide implementation programme in 2016, Recipharm has already delivered over 1.3 million serialised and aggregated packs to markets such as China, South Korea, Saudi Arabia and Turkey where serialisation regulations are currently in place.
Staffan Widengren, Director of Corporate Projects at Recipharm and head of the global steering committee for Recipharm’s serialisation project said: “We’ve taken a very proactive approach to tackling serialisation as we understand the critical role that contract manufacturers must play in ensuring continuous supply of vital medicines in key markets. In addition to equipping nine of our sites ahead of the EU deadline and the new US enforcement date, we’ve also introduced a serialisation task force to ensure a consistent roll out of our standard solution across all of our facilities.”
“While the FDA has announced a grace period ahead of the DSCSA deadline, companies can still be penalised for failing to meet the mandate by the 27th November 2017. With this in mind, it was important to ensure we could offer serialisation capabilities by the original US deadline to avoid potential problems for our customers.”
“The investment we’ve made in terms of time, money and resource means we’re well prepared ahead of time and a lot of our customers are already on-boarded. We can now refocus our attention on ensuring we realise the additional benefits of serialisation implementation including improving line efficiencies and streamlining logistics operations.”
The next facilities to be equipped will be the company’s facility in Bengaluru, India, which will supply serialised products for the US.
Contact information
Staffan Widengren, Director Corporate Projects, staffan.widengren@recipharm.com, +46 8 6024 475
For media enquiries, please contact Lindsay Baldry at ramarketing: lindsay@ramarketingpr.com, + 44 (0)191 222 1242, www.ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, LinkedIn: /ramarketing
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com.
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com
Tags: